


**CLAIMS**

1. A compound



1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea, or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1, wherein the compound is a dihydrochloride salt of 1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea.

3. A pharmaceutical composition, which comprises a compound of claim 1 or 2, and a pharmaceutically acceptable diluent or carrier.

4. The pharmaceutical composition according to claim 3, wherein said pharmaceutical composition is formulated for oral administration.

5. The pharmaceutical composition according to claim 4, wherein said pharmaceutical composition is in the form of a tablet or capsule.

6. The compound according to claim 1 or 2 for use in the treatment of a disease or disorder selected from the group consisting of pain, cancer, inflammation or an inflammatory diseases, neurodegenerative diseases, Trypanosoma cruzi infection, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, pelvic pain syndrome, osteoporosis, rheumatoid arthritis, bone metastases, Raynaud's Syndrome, Idiopathic

pulmonary fibrosis, scarring, cirrhosis, endomyocardial fibrosis, atrial fibrosis, myelofibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis, scleroderma, systemic sclerosis, arthrofibrosis and ocular fibrosis.

7. The compound for use according to claim 6, wherein the disorder is pain.
8. The compound for use according to claim 7, wherein said pain is chronic pain.
9. The compound for use according to claim 8, wherein said chronic pain is chronic back pain.
10. The compound for use according to claim 7, wherein said pain is acute pain.
11. The compound for use according to claim 7, wherein said pain is selected from the group consisting of neuropathic pain, inflammatory pain, pain associated with cancer, pain associated with bone fracture, and pain associated with surgery.
12. The compound for use according to claim 11, wherein said pain is neuropathic pain.
13. The compound for use according to claim 12, wherein said neuropathic pain is pain associated with diabetic peripheral neuropathy.
14. The compound for use according to claim 11, wherein said pain is inflammatory pain.
15. The compound for use according to claim 14, wherein said inflammatory pain is pain associated with osteoarthritis.
16. The compound for use according to claim 11, wherein said pain is pain associated with cancer.

17. The compound for use according to claim 11, wherein said pain is pain associated with bone fracture.

18. The compound for use according to claim 11, wherein said pain is pain associated with surgery.

19. The compound for use according to any one of claims 7-18, wherein the compound or a pharmaceutically acceptable salt thereof is to be administered in combination with an effective amount of at least one additional therapeutic agent selected from the group consisting of anti-inflammatory compounds, steroids, analgesics, opioids, calcitonin gene-related peptide receptor antagonists, subtype-selective ion channel modulators, anticonvulsants, dual serotonin-norepinephrine reuptake inhibitors, JAK family kinase inhibitors, and tricyclic antidepressants.

20. The compound for use according to claim 19, wherein the analgesic is an NSAID.

21. The compound for use according to claim 6, wherein said disease is an inflammatory disease.

22. The compound for use according to claim 21, wherein the inflammatory disease is selected from the group consisting of inflammatory lung diseases, interstitial cystitis, painful bladder syndrome, inflammatory bowel diseases, and inflammatory skin diseases.

23. The compound for use according to claim 22, wherein the inflammatory disease is interstitial cystitis.

24. The compound for use according to claim 22, wherein the inflammatory disease is painful bladder syndrome.

25. The compound for use according to any one of claims 21-24, wherein the compound or a pharmaceutically acceptable salt thereof is to be administered in combination with an effective amount of one or more additional agents selected from the group consisting of anti-TNF agents, antimetabolite and antifolate drugs, and targeted kinase inhibitors.

26. The compound for use according to claim 25, wherein the compound or a pharmaceutically acceptable salt thereof is to be administered in combination with an effective amount of one or more additional agents selected from the group consisting of infliximab, adalimumab, certolizumab pegol, golimumab, etanercept, Methotrexate, Ruxolitinib, Tofacitinib, CYT387, Lestaurtinib, Pacritinib and TG101348.

27. The compound for use according to claim 6, wherein the disease is selected from the group consisting of Raynaud's Syndrome, Idiopathic pulmonary fibrosis, scarring, cirrhosis, endomyocardial fibrosis, atrial fibrosis, myelofibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis, scleroderma, systemic sclerosis, arthrofibrosis, and ocular fibrosis.

28. The compound for use according to claim 6, wherein said disease is cancer.

29. The compound for use according to claim 28, wherein said cancer comprises one or more TrkA gene fusions, one or more deletions, insertions or mutations in a TrkA protein, or an overexpression of wild-type TrkA.

30. The compound for use according to claim 29, wherein the TrkA gene fusion is LMNA-TrkA, TFG-TrkA, TPM3-TrkA, CD74-TrkA, NFASC-TrkA, MPRIP-TrkA, BCAN-TrkA, TP53-TrkA, RNF213-TrkA, RABGAP1L-TrkA, IRF2BP2-TrkA, SQSTM1-TrkA, SSBP2-TrkA, or TPR-TrkA.

31. The compound for use according to claim 30, wherein said cancer is non-small cell lung cancer, papillary thyroid carcinoma, glioblastoma multiforme, colorectal carcinoma, melanoma, cholangiocarcinoma, or sarcoma.

32. The compound for use according to claim 29, wherein said cancer is acute myeloid leukemia, large cell neuroendocrine carcinoma, or neuroblastoma.

33. The compound for use according to claim 29, wherein said cancer comprises an overexpression of wild-type TrkA.

34. The compound for use according to claim 33, wherein the cancer is prostate carcinoma, neuroblastoma, pancreatic carcinoma, melanoma, head and neck squamous cell carcinoma, or gastric carcinoma.

35. The compound for use according to any one of claims 29-34, wherein the compound or a pharmaceutically acceptable salt thereof is to be administered in combination with an effective amount of at least one additional therapeutic agent selected from one or more additional therapy or chemotherapeutic agent.


36. The compound for use according to claim 35, wherein said additional therapy or chemotherapeutic agent is selected from radiotherapy, cytotoxic chemotherapeutics, tyrosine kinase targeted-therapeutics, apoptosis modulators, signal transduction inhibitors, immune-targeted therapies and angiogenesis-targeted therapies.

37. The compound for use according to claim 36 wherein said chemotherapeutic agent is selected from tyrosine kinase targeted-therapeutics.


38. Use of the compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, Trypanosoma cruzi infection, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, pelvic pain syndrome, osteoporosis, rheumatoid arthritis, bone metastases, Raynaud's Syndrome, Idiopathic pulmonary fibrosis, scarring, cirrhosis, endomyocardial fibrosis, atrial fibrosis, myelofibrosis, progressive massive fibrosis (lung), nephrogenic systemic fibrosis, scleroderma, systemic sclerosis, arthrofibrosis and ocular fibrosis.

39. A process for the preparation of a compound of claim 1 or 2, which comprises:

(a) reacting a compound having the formula **II-A**




with a compound having the formula **III**




in the presence carbonyldiimidazole or triphosgene and a base; or

(b) reacting a compound having the formula **II-A**




with a compound having the formula **IV**




where  $L^1$  is a leaving group, in the presence of a base; or

(c) reacting a compound having the formula **V**


**V**

where  $L^2$  is a leaving group, with a compound having the formula **III**


**III**

in the presence of a base; or

(d) reacting a compound having the formula **VI**


**VI**

with diphenylphosphoryl azide to form an intermediate, followed by reacting the intermediate with a compound having the formula **III**


**III**

in the presence a base; or

(e) reacting a compound having the formula **II-A**

**II-A**

with a compound having the formula **VII**



in the presence of a base; and

(f) removing and protecting groups if present and optionally preparing a pharmaceutically acceptable salt thereof.